Double Filtration Plasmapheresis for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Double Filtration Plasmapheresis for Health & Longevity

Created on 08/29/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A machine procedure that filters the largest molecules out of blood. Where a specific harmful large molecule is present and measured, it clears that molecule quickly, and in antibody-driven nerve and muscle disease symptoms improve. It also strips clotting proteins, antibodies and fat-soluble vitamins. Outside a qualifying diagnosis the longevity case rests on a different procedure. (Full Review)

Protocol

Standard disease protocol
3–6 sessions, alternate days
Antibody-mediated disease; 1.0–1.5 plasma volumes per session with 5% albumin replacement. Repeated only if the target antibody or symptom rebounds.
Standard metabolic protocol
Weekly or fortnightly, indefinitely
For elevated lipoprotein(a) or familial hypercholesterolaemia; removal is not curative and levels return toward baseline within days.
Longevity-clinic protocol
4–6 sessions over 2–3 months
Then 2–4 maintenance sessions annually. No published trial has evaluated this schedule against any endpoint.
Time to effect
Symptomatic change
5–7 days
In antibody-mediated disease; peaks after a full course.
Molecular effects
Immediate
Target molecules fall within a single 2–3 hour session.
Half-life and rebound
Days to weeks
Fibrinogen and albumin recover over 2–3 days, immunoglobulin G over 3–4 weeks, lipoprotein(a) within days.

Benefits

Contraindications
  • Angiotensin-converting-enzyme inhibitors (lisinopril, ramipril) with negatively charged filters
  • Active bleeding, or fibrinogen below 1.0 g/L
  • Unstable blood pressure or circulation, or New York Heart Association Class IV heart failure
  • Symptomatic coronary artery disease, or myocardial infarction (heart attack) within 90 days
  • Active systemic infection or sepsis
  • Severe uncorrected anaemia (haemoglobin below 8 g/dL)
  • Known allergy to the filter membrane material, or to heparin where citrate is unavailable
  • Poor peripheral vascular access with no acceptable central option
  • Pregnancy outside a specialist centre and a life-threatening indication
  • Active malignancy under treatment, and late-stage Alzheimer's disease
    •
Key Interactions
  • Anticoagulants (warfarin, apixaban, heparin)
  • Antiplatelet drugs (aspirin, clopidogrel)
  • Monoclonal antibody therapies (rituximab, efgartigimod, evolocumab)
  • Over-the-counter non-steroidal anti-inflammatories (ibuprofen, naproxen)
  • Fish oil, high-dose vitamin E, ginkgo, garlic and nattokinase
  • Calcium and magnesium supplements
  • Fat-soluble vitamins and carotenoids (vitamins A, D, E, K)
  • Other interventions (lipid-lowering drugs, immunoglobulin infusion, immunosuppressants)
    •

Risk & Side Effects

  • High: Depletion of clotting factors and bleeding risk; low blood pressure during and after treatment
    •
  • Medium: Rupture of red blood cells from rising filter pressure; immunoglobulin depletion and infection risk; citrate-related low calcium; albumin and total protein loss; hypersensitivity reactions to the circuit and replacement fluid
    •
  • Low: Vascular access complications; liver enzyme elevation; platelet loss across the circuit
    •
  • Speculative: Rebound redistribution of stored toxins; removal of beneficial circulating factors
    •

Monitoring

Marker Target Why
Fibrinogen 2.0–4.0 g/L before each session Sets bleeding risk; the most depleted protein
Ionised (unbound) calcium 1.15–1.30 mmol/L Detects citrate-driven falls causing tingling and cramps
Magnesium 0.85–1.00 mmol/L Falls alongside calcium and is routinely missed
Albumin 4.2–5.0 g/dL Holds fluid inside vessels; drives mid-session blood-pressure stability
Immunoglobulin G 7.0–14.0 g/L Tracks cumulative antibody loss and infection exposure
Lipoprotein(a) Below 30 mg/dL (75 nmol/L) Primary metabolic target; genetically fixed and diet-resistant
LDL cholesterol Below 70 mg/dL (1.8 mmol/L) Main artery-clogging cholesterol carrier; secondary metabolic target
High-sensitivity C-reactive protein Below 1.0 mg/L Tracks the inflammatory claim; must be abnormal at baseline to improve
Platelet count 200–350 × 10⁹/L Falls with circuit exposure and compounds bleeding risk
Prothrombin time / INR 0.9–1.1 Detects the broader clotting-factor deficit beyond fibrinogen
Haemoglobin 13.5–15.0 g/dL (men), 12.5–14.0 (women) Detects red-cell rupture and dilution; low values worsen blood-pressure falls
eGFR and creatinine eGFR above 90 mL/min/1.73 m² Free haemoglobin from ruptured red cells burdens the kidneys

Cadence: Full baseline panel before any course. During a course, fibrinogen, unbound calcium and a full blood count before every session, with the target molecule measured before and after the first session. After a course, the target molecule and immunoglobulin G at 2 and 12 weeks, then every 6–12 months on maintenance.

Qualitative Assessment

  • Energy and exercise tolerance in the 48 hours after each session
  • Light-headedness on standing, the earliest sign that replacement fluid is under-prescribed
  • Unusual bruising, gum bleeding or prolonged bleeding from small cuts
  • Tingling around the mouth or fingers and muscle cramps
  • Dark or cola-coloured urine after a session
  • Cognitive clarity and sleep quality across a course
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.